You can now read 10 articles a month for free. Read as much as you want anywhere and anytime for just 99¢.

Gen9 gets $21m boost from Agilent

Agilent Technologies Inc. has made a $21 million investment in Gen9 Inc., a Cambridge company specializing in gene synthesis.

Customers can potentially use Gen9’s technology to more efficiently make everything from fabrics and chemicals to drugs and renewable fuels.

Continue reading below

According to Gen9, methods using its technology are more cost-effective than traditional methods.

Headquartered in California, Agilent is a $6.9 billion company focused on chemical analysis, life sciences, ­diagnostics, electronics, and communications.

In a press release, Agilent said its partnership with Gen9 complements Agilent’s existing investments in synthetic biology and gene synthesis.

Agilent is taking an equity stake in Gen9.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week